A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled,
multicenter study designed to evaluate the safety and tolerability of efalizumab administered
subcutaneously at weekly doses of 1.0 mg/kg in subjects with moderate to severe plaque
psoriasis who are candidates for systemic therapy.